Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on SHR6390 (Dalpiciclib) Pharmacokinetics
NCT04423601Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration (Cmax) of SHR6390 at 32 days and Area Under the Curve (AUC) of SHR6390 at 32 days. Started Jun 2020; status: completed.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04423601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423601.